Home > Publications Database > Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry. > print

001     164977
005     20230915090603.0
024 7 _ |a 10.3390/cancers14143363
|2 doi
024 7 _ |a pmid:35884425
|2 pmid
024 7 _ |a pmc:PMC9317824
|2 pmc
024 7 _ |a altmetric:133300570
|2 altmetric
037 _ _ |a DZNE-2022-01381
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Dumont, Martine
|0 0000-0002-5488-4839
|b 0
245 _ _ |a Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry.
260 _ _ |a Basel
|c 2022
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1659706040_13580
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a CC BY
520 _ _ |a Rare variants in at least 10 genes, including BRCA1, BRCA2, PALB2, ATM, and CHEK2, are associated with increased risk of breast cancer; however, these variants, in combination with common variants identified through genome-wide association studies, explain only a fraction of the familial aggregation of the disease. To identify further susceptibility genes, we performed a two-stage whole-exome sequencing study. In the discovery stage, samples from 1528 breast cancer cases enriched for breast cancer susceptibility and 3733 geographically matched unaffected controls were sequenced. Using five different filtering and gene prioritization strategies, 198 genes were selected for further validation. These genes, and a panel of 32 known or suspected breast cancer susceptibility genes, were assessed in a validation set of 6211 cases and 6019 controls for their association with risk of breast cancer overall, and by estrogen receptor (ER) disease subtypes, using gene burden tests applied to loss-of-function and rare missense variants. Twenty genes showed nominal evidence of association (p-value < 0.05) with either overall or subtype-specific breast cancer. Our study had the statistical power to detect susceptibility genes with effect sizes similar to ATM, CHEK2, and PALB2, however, it was underpowered to identify genes in which susceptibility variants are rarer or confer smaller effect sizes. Larger sample sizes would be required in order to identify such genes.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a breast cancer
|2 Other
650 _ 7 |a genetic susceptibility
|2 Other
650 _ 7 |a moderate-penetrance genes
|2 Other
650 _ 7 |a whole-exome sequencing
|2 Other
700 1 _ |a Weber-Lassalle, Nana
|b 1
700 1 _ |a Joly-Beauparlant, Charles
|b 2
700 1 _ |a Ernst, Corinna
|0 0000-0001-7756-8815
|b 3
700 1 _ |a Droit, Arnaud
|b 4
700 1 _ |a Feng, Bing-Jian
|b 5
700 1 _ |a Dubois, Stéphane
|b 6
700 1 _ |a Collin-Deschesnes, Annie-Claude
|b 7
700 1 _ |a Soucy, Penny
|b 8
700 1 _ |a Vallée, Maxime
|b 9
700 1 _ |a Fournier, Frédéric
|b 10
700 1 _ |a Lemaçon, Audrey
|0 0000-0002-1817-7029
|b 11
700 1 _ |a Adank, Muriel A
|b 12
700 1 _ |a Allen, Jamie
|0 0000-0002-8677-2225
|b 13
700 1 _ |a Altmüller, Janine
|b 14
700 1 _ |a Arnold, Norbert
|b 15
700 1 _ |a Ausems, Margreet G E M
|0 0000-0003-0305-3477
|b 16
700 1 _ |a Berutti, Riccardo
|b 17
700 1 _ |a Bolla, Manjeet K
|b 18
700 1 _ |a Bull, Shelley
|0 0000-0002-3280-7154
|b 19
700 1 _ |a Carvalho, Sara
|b 20
700 1 _ |a Cornelissen, Sten
|b 21
700 1 _ |a Dufault, Michael R
|b 22
700 1 _ |a Dunning, Alison M
|b 23
700 1 _ |a Engel, Christoph
|0 0000-0002-7247-282X
|b 24
700 1 _ |a Gehrig, Andrea
|b 25
700 1 _ |a Geurts-Giele, Willemina R R
|b 26
700 1 _ |a Gieger, Christian
|b 27
700 1 _ |a Green, Jessica
|0 0000-0002-7005-2928
|b 28
700 1 _ |a Hackmann, Karl
|b 29
700 1 _ |a Helmy, Mohamed
|b 30
700 1 _ |a Hentschel, Julia
|b 31
700 1 _ |a Hogervorst, Frans B L
|b 32
700 1 _ |a Hollestelle, Antoinette
|0 0000-0003-1166-1966
|b 33
700 1 _ |a Hooning, Maartje J
|b 34
700 1 _ |a Horváth, Judit
|b 35
700 1 _ |a Ikram, M Arfan
|b 36
700 1 _ |a Kaulfuß, Silke
|0 0000-0003-2577-9711
|b 37
700 1 _ |a Keeman, Renske
|b 38
700 1 _ |a Kuang, Da
|0 0000-0003-3554-0464
|b 39
700 1 _ |a Luccarini, Craig
|b 40
700 1 _ |a Maier, Wolfgang
|0 P:(DE-2719)2000015
|b 41
|u dzne
700 1 _ |a Martens, John W M
|0 0000-0002-3428-3366
|b 42
700 1 _ |a Niederacher, Dieter
|b 43
700 1 _ |a Nürnberg, Peter
|0 0000-0002-7228-428X
|b 44
700 1 _ |a Ott, Claus-Eric
|0 0000-0003-3627-3791
|b 45
700 1 _ |a Peters, Annette
|0 0000-0001-6645-0985
|b 46
700 1 _ |a Pharoah, Paul D P
|b 47
700 1 _ |a Ramirez, Alfredo
|0 P:(DE-2719)2812825
|b 48
|u dzne
700 1 _ |a Ramser, Juliane
|b 49
700 1 _ |a Riedel-Heller, Steffi
|b 50
700 1 _ |a Schmidt, Gunnar
|b 51
700 1 _ |a Shah, Mitul
|b 52
700 1 _ |a Scherer, Martin
|b 53
700 1 _ |a Stäbler, Antje
|b 54
700 1 _ |a Strom, Tim M
|b 55
700 1 _ |a Sutter, Christian
|b 56
700 1 _ |a Thiele, Holger
|b 57
700 1 _ |a van Asperen, Christi J
|b 58
700 1 _ |a van der Kolk, Lizet
|b 59
700 1 _ |a van der Luijt, Rob B
|b 60
700 1 _ |a Volk, Alexander E
|b 61
700 1 _ |a Wagner, Michael
|0 P:(DE-2719)2000057
|b 62
|u dzne
700 1 _ |a Waisfisz, Quinten
|b 63
700 1 _ |a Wang, Qing
|0 P:(DE-2719)9000806
|b 64
|u dzne
700 1 _ |a Wang-Gohrke, Shan
|b 65
700 1 _ |a Weber, Bernhard H F
|0 0000-0002-8808-7723
|b 66
700 1 _ |a Genome Of The Netherlands Project
|b 67
700 1 _ |a Ghs Study Group
|b 68
700 1 _ |a Devilee, Peter
|0 0000-0002-8023-2009
|b 69
700 1 _ |a Tavtigian, Sean
|b 70
700 1 _ |a Bader, Gary D
|0 0000-0003-0185-8861
|b 71
700 1 _ |a Meindl, Alfons
|b 72
700 1 _ |a Goldgar, David E
|b 73
700 1 _ |a Andrulis, Irene L
|0 0000-0002-4226-6435
|b 74
700 1 _ |a Schmutzler, Rita K
|b 75
700 1 _ |a Easton, Douglas F
|b 76
700 1 _ |a Schmidt, Marjanka K
|0 0000-0002-2228-429X
|b 77
700 1 _ |a Hahnen, Eric
|b 78
700 1 _ |a Simard, Jacques
|0 0000-0001-6906-3390
|b 79
770 _ _ |a Hereditary Breast Cancer in Men and Women: Genetic Mutations, Cancer Risk and Treatment
773 _ _ |a 10.3390/cancers14143363
|g Vol. 14, no. 14, p. 3363 -
|0 PERI:(DE-600)2527080-1
|n 14
|p 3363
|t Cancers
|v 14
|y 2022
|x 2072-6694
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/164977/files/DZNE-2022-01381.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/164977/files/DZNE-2022-01381.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:164977
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 41
|6 P:(DE-2719)2000015
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 48
|6 P:(DE-2719)2812825
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 62
|6 P:(DE-2719)2000057
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 64
|6 P:(DE-2719)9000806
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-05-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-05-04
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-05-04
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-05-04
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCERS : 2021
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-01-24T07:56:58Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-01-24T07:56:58Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2022-01-24T07:56:58Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-30
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-30
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CANCERS : 2021
|d 2022-11-30
920 1 _ |0 I:(DE-2719)1011001
|k AG Klockgether
|l Clinical Research- coordination
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1011001
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21